Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

75.0%

3 terminated/withdrawn out of 4 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04304781Phase 1Terminated

Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer

Role: lead

NCT03594331Phase 1Terminated

Gastric Gluten-Degradation Activity of PvP001

Role: lead

NCT03148119Phase 1Terminated

Study of QRH-882260 Heptapeptide Application in the Colon

Role: lead

NCT02156557Phase 1Completed

Study of KCC Peptide Application in the Colon

Role: lead

All 4 trials loaded